跳至主要内容
临床试验/CTRI/2021/12/038569
CTRI/2021/12/038569招募中1 期

EVALUATING CLINICAL EFFICACY OF VIRECHAN AND RASAYAN THERAPY (GO-MUTRA HARITAKI) IN THE MANAGEMENT OF HRUDROGA (CORONARY ARTERY DISEASES)- A RANDOMIZED CONTROL CLINICAL TRIA

All India Institute of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Both sex
  • 2. Age group between 20-70 years
  • 3. Class I, II&IIa (III) as per Canadian Cardiovascular Society grading of angina pectoris
  • 4.CAC Scoring < 400/ <90 percentile
  • 5. ECG- T wave inverted without Q wave / ST elevation
  • 6.Stress TMT- Positive
  • 7. Angiography- <60% occlusion in any of the coronary artery
  • 8. Those are able to give written consent

排除标准

  • 1.Renal insufficiency (S. Creatinine > 2 mg/dl, Blood Urea > 40 mg/dl)
  • 2.â?•2D ECHO showing the presence of any valvular heart disease
  • 3.Tachycardia( >160/min)/ Ventricular arrhythmia
  • 4. Low Left Ventricular Ejection Fraction (LVEF < 40%)
  • 4.â?•Positive Troponin Test
  • 5.CT Angiography lesion > 60%
  • 6.â?•CPK-MB > 5%
  • 7. Prolonged or traumatic cardiovascular resuscitation
  • 8. Previous Coronary Intervention (within 3 months) or any bypass surgery
  • 9. Ischemic Cerebral stroke within past one months
  • 10. Peripheral arterial diseases
  • 11. Recent Head trauma or known intracranial neoplasm
  • 12. Suspected aortic dissection
  • 13. Prolonged chest pain ( > 30mints) associated with vomiting and syncope
  • 14. Chest pain with vagotonia (bradycardia, pallor, and syncope)
  • 15. Haemorrhagic stroke within past one month
  • 16. Diabetic haemorrhagic retinopathy or other haemorrhagicopthalamic conditions.
  • 17. Recorded uncontrolled Blood Pressure >180/100mmHg in three consecutive readings
  • 18. Active peptic ulcer
  • 19. Significant liver dysfunction
  • 20.â?•Raised Prothrombin time, Activated Partial Thromboplastin Time
  • 21.â?•Heart failure (Brain Natriuretic Peptide > 2 times)
  • 22. Active bleeding, Known bleeding diathesis or current use of anticoagulant
  • 23. BMI <18
  • 24. All VirechanAnarha patients as mentioned in Ch. Si 2/11 will be excluded
  • VirechanAnarha are Subhag, Kshatgud, Muktanal, Adhog Raktapitta, Vilanghit,Durbal, Alpagni, Adivya nirudhaka, Ajirna, Nawajwar, Madatyay, Aadhman, Shalyadrit, Atisnigdha, Atiruksha, Krurkoshtha, Urahkshat, Kshina, Atisthul, Atikrusha, Garbhini.
  • Any other case if investigator feels could not include in the study during the course of study
  • (â?• Investigation will be done if feasible)

研究者

相似试验